Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mania and Antimanic Drugs: Overview

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of Metformin on Healthspan-Related Outcomes and Incidence of Diseases of Aging in People with Type 2 Diabetes Mellitus: A Systematic Review.

Rejuvenation research·2026

Same author

Allopregnanolone Concentrations After Ascending Single Dose Administration of Progesterone to Healthy Volunteers.

Human psychopharmacology·2025

Same author

Management of Relapsing Catatonia After Lorazepam Discontinuation: A Systematic Review of Published Case Reports.

Journal of the Academy of Consultation-Liaison Psychiatry·2025

Same author

Are Baby Boomers hazardous drinkers as they age? An exploratory interRAI study.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists·2025

Same author

Loneliness in older persons with schizophrenia.

The International journal of social psychiatry·2024

Same author

Effects of changing criteria on improving interRAI assessment for elder abuse: analysis of a national dataset from Aotearoa New Zealand.

BMJ open·2024

Search research articles

Related Experiment Videos

Asenapine for elderly bipolar manic patients.

Yehuda Baruch¹, Shelly Tadger, Igor Plopski

¹Tel-Aviv university, Sackler School of Medicine, Abarbanel Mental Health Center, 15 KKL Street, 59100 Bat-Yam, Israel.

Journal of Affective Disorders

|August 11, 2012

Summary

Asenapine effectively treated bipolar mania in elderly patients, showing significant symptom improvement and a high remission rate within four weeks. This study indicates asenapine is a well-tolerated option for late-life bipolar disorder management.

Related Experiment Videos

Area of Science:

Geriatric Psychiatry
Pharmacology
Clinical Therapeutics

Background:

Late-life bipolar disorder (BPD) presents complex challenges with limited treatment data.
Asenapine is FDA-approved for acute manic/mixed episodes in bipolar I disorder.

Purpose of the Study:

To evaluate the efficacy and safety of asenapine in elderly patients with acute bipolar mania.

Main Methods:

An open-label study treated 11 elderly patients (mean age 67.7 years) with asenapine 10mg BID for 4 weeks.
Safety was assessed via adverse events, labs, and anthropometrics.
Efficacy was measured by changes in the Young Mania Rating Scale (YMRS).

Main Results:

7/11 (63.6%) patients achieved remission (YMRS ≤ 12).
Mean YMRS score improved by -21.4 ± 12.9.
Adverse events were mild, including rash and edema in one patient each, and mild sedation in three patients.

Conclusions:

Asenapine demonstrated good tolerability and effectiveness in this small cohort of elderly patients with bipolar mania.
The findings support asenapine as a viable acute treatment option for this population.